The Phase I trial of the Survivin long peptide vaccine (SurVaxM) is sponsored by Roswell Park Cancer Institute and focuses on patients with metastatic neuroendocrine tumors (NETs). Given the limited treatment options for advanced NETs, this vaccine could represent a novel immunotherapeutic approach, potentially enhancing the immune response against tumors expressing survivin. The market for NET therapies is growing, with increasing incidence rates and a demand for innovative treatments. Competitive analysis indicates that while somatostatin analogs are standard care, there is a gap for immunotherapies, positioning SurVaxM favorably. Diligence should focus on safety and efficacy data as well as potential partnerships for further development and commercialization.